Gilead says that the drug has delayed tumor growth in the aggressive form of breast cancer

Adam Feuerstein is a main writer and biotechnology columnist, reporting on the crossroads of drug development, business, Wall Street and biotechnology. He is also co-host of the weekly biotech podcast The Readout Loud and author of the Biotech dashboard of the Adam newsletter. You can reach Adam on the signal to stataf.54.

Gilead Sciences said on Monday that a combination of his cancer drug Trodelvy and Merck Keytruda had delayed the growth of tumors in women with a less common but aggressive form of breast cancer.

The results of a randomized phase 3 study called ASCENT-04 could lead to a new treatment option for patients with newly diagnosed triple negative breast. Gilead could also benefit from a boost in Trodelvy sales at a time when he faces the competition from a similar medication made by Astrazeneca and Daiichi Sankyo.

In the study, the combination of Trodelvy and Keytruda has demonstrated a “clinically significant” improvement in unprofessional survival compared to Keytruda more chemotherapy – achieving the main effectiveness of the study, Gilead said.